Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 2/20 | 0.36 |
| ▸ | NAMPT | P43490 | 9/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | IDH1 | O75874 | 2/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.34 |
| ▸ | CCNK | O75909 | 1/20 | 0.34 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | CCND3 | P30281 | 1/20 | 0.34 |
| ▸ | CDK9 | P50750 | 1/20 | 0.34 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | IDH2 | P48735 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29326245 | 0.89 | IDH1 (0.38) | BTKPOLBIDH1USP30CCNK | |
| SCHEMBL29325929 | 0.81 | BTK (0.49) | BTKIDH1USP30IDH2HTT | |
| SCHEMBL29326041 | 0.79 | BTK (0.50) | BTKIDH1USP30 | |
| SCHEMBL30488538 | 0.79 | BTK (0.50) | BTKIDH1USP30 | |
| SCHEMBL25302818 | 0.79 | BTK (0.50) | BTKIDH1USP30 | |
| SCHEMBL25302816 | 0.79 | BTK (0.50) | BTKIDH1USP30 | |
| SCHEMBL31341798 | 0.78 | CDK4 (0.39) | BTKPOLBIDH1USP30CCND3 | |
| SCHEMBL29325933 | 0.78 | CDK4 (0.46) | BTKPOLBIDH1USP30CCND3 | |
| SCHEMBL29326283 | 0.77 | NLRP3 (0.42) | IDH1IDH2 | |
| SCHEMBL29325970 | 0.77 | CDK4 (0.37) | POLBUSP30CCND3CDK6HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239758-A1 | SUBSTITUTED TRIAZINE COMPOUND | NICO THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239758-A1 | SUBSTITUTED TRIAZINE COMPOUND | NLRP3, NLRP1, PYCARD | BTK 2826/4885NAMPT 602/4885POLB 4733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.